Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor–Based Therapy in Patients With Advanced Non–Small-Cell Lung Cancer
Open accessAbstract
This cohort study examines the association of KRAS status with outcomes following immune checkpoint inhibition monotherapy vs chemoimmunotherapy.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Initial data suggest higher tumor mutational burden occurs in the overall KRAS mutant population, potentially improving response to immune checkpoint inhibition.
“Initial data suggest that a higher tumor mutational burden occurs in the overall KRAS mutant population, potentially resulting in improved response to immune checkpoint inhibition (71).”
From Expanding the Reach of Precision Oncology by Drugging All <i>KRAS</i> Mutants (2022) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Mok, T. S. K., Wu, Y.-L. L. C., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., de Castro, G., Srimuninnimit, V., Лактионов, К. К., Bondarenko, I., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32409-7 · Cited by 3,319 · see citing works
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
Coelho, M. A., de Carné Trécesson, S., Rana, S., Zecchin, D., Moore, C., Molina-Arcas, M., East, P., Spencer-Dene, B., Nye, E., Barnouin, K., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.11.016 · Cited by 653 · see citing works
Ma, X., Long, L., Moon, S., Adamson, B. J. S., & Baxi, S. S. (2020) · medRxiv · doi:10.1101/2020.03.16.20037143 · Cited by 358 · see citing works
Liu, C., Zheng, S., Jin, R., Wang, X., Wang, F., Zang, R., Xu, H., Lu, Z., Huang, J., Lei, Y., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.10.027 · Cited by 281 · see citing works
Herbst, R. S., Lopes, G. D. L., Jr., Kowalski, D. M., Kasahara, K., Wu, Y., de Castro, G., Cho, B. C., Turna, H. Z., Cristescu, R., Aurora-Garg, D., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz453.001 · Cited by 91 · see citing works
Association of the COVID-19 Outbreak With Patient Willingness to Enroll in Cancer Clinical Trials.
Fleury, M. E., Farner, A. M., & Unger, J. M. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.5748 · Cited by 50 · see citing works
Kartolo, A., Feilotter, H. E., Hopman, W. M., Fung, A. S., & Robinson, A. G. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100330 · Cited by 27 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Expanding the Reach of Precision Oncology by Drugging All <i>KRAS</i> Mutants
Hofmann, M. H., Gerlach, D., Misale, S., Petronczki, M., & Kraut, N. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1331 · Cited by 336 · see citing works
Reckamp, K. L., Redman, M. W., Dragnev, K. H., Minichiello, K., Villaruz, L. C., Faller, B. A., Baghdadi, T. A., Hines, S. J., Everhart, L., Highleyman, L., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00912 · Cited by 237 · see citing works
Liu, C., Zheng, S., Wang, Z., Wang, S., Wang, X., Yang, L., Xu, H., Cao, Z., Feng, X., Xue, Q., et al. (2022) · 癌症：英文版 · doi:10.1002/cac2.12327 · Cited by 181 · see citing works
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms
Yang, X., & Wu, H. K. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01631-9 · Cited by 123 · see citing works
Salem, M. E., El-Refai, S. M., Sha, W., Puccini, A., Grothey, A., George, T. J., Hwang, J. J., O’Neil, B. H., Barrett, A. S., Kadakia, K. C., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00245 · Cited by 110 · see citing works
Emerging evidence and treatment paradigm of non-small cell lung cancer
Liu, S. M., Zheng, M.-M., Pan, Y., Liu, S. M., Li, Y., & Wu, Y.-L. L. C. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01436-2 · Cited by 105 · see citing works
Unveiling the role of KRAS in tumor immune microenvironment
Xu, M., Zhao, X., Wen, T., & Qu, X. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116058 · Cited by 93 · see citing works
Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR
Seegobin, K., Majeed, U., Wiest, N. E., Manochakian, R., Lou, Y., & Zhao, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.750657 · Cited by 81 · see citing works
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Tang, D., Kroemer, G., & Kang, R. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01422-7 · Cited by 80 · see citing works
Yang, Y., Zhang, H., Huang, S., & Chu, Q. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12020709 · Cited by 76 · see citing works
KRAS in NSCLC: State of the Art and Future Perspectives
Cascetta, P., Marinello, A., Lazzari, C., Gregorc, V., Planchard, D., Bianco, R., Normanno, N., & Morabito, A. (2022) · Cancers · doi:10.3390/cancers14215430 · Cited by 76 · see citing works
Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
Désage, A.-L., Léonce, C., Swalduz, A., & Ortiz‐Cuaran, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.796832 · Cited by 60 · see citing works
Laguna, J. C., García-Pardo, M., Alessi, J. V., Barrios, C. H., Singh, N., Al-Shamsi, H. O., Loong, H. H.-F., Ferriol, M., Recondo, G., & Mezquita, L. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241231260 · Cited by 60 · see citing works
KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways
Mondal, K., Posa, M. K., Shenoy, R. P., & Roychoudhury, S. (2024) · Cells · doi:10.3390/cells13141221 · Cited by 56 · see citing works
Liu, R., Rizzo, S., Waliany, S., Garmhausen, M. R., Pal, N., Huang, Z., Chaudhary, N., Wang, L. E., Harbron, C. G., Neal, J. W., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01873-5 · Cited by 53 · see citing works
Li, M., Jiang, P., Wei, S., Wang, J., & Li, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1113312 · Cited by 50 · see citing works
Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer
Vokes, N. I., Pan, K., & Le, X. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231161409 · Cited by 39 · see citing works
Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases
Lauko, A. J., Kotecha, R. R., Barnett, A. E., Li, H., Tatineni, V., Ali, A., Patil, P. D., Mohammadi, A. M., Chao, S. T., Murphy, E. S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-97566-z · Cited by 35 · see citing works
Shitara, K., Janjigian, Y. Y., Ajani, J. A., Moehler, M. H., Yao, J. G., Wang, X., Chhibber, A., Pandya, D., Shen, L., Marcelo Garrido, S., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03575-0 · Cited by 32 · see citing works
Targeting KRAS in Non-Small Cell Lung Cancer
de la Fuente, E. C., Olmedo, M. E., Rueda, A. G., Lage, Y., & Garrido, P. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.792635 · Cited by 33 · see citing works
Cefalì, M., Epistolio, S., Ramelli, G., Mangan, D., Molinari, F., Martin, V., Freguia, S., Mazzucchelli, L., Froesch, P., Frattini, M., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11061627 · Cited by 28 · see citing works
Manolakos, P., & Ward, L. D. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13061010 · Cited by 27 · see citing works
Galland, L., Page, A. L. L., Lecuelle, J., Bibeau, F., Oulkhouir, Y., Dérangère, V., Truntzer, C., & Ghiringhelli, F. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1957603 · Cited by 27 · see citing works
Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers
Cekani, E., Epistolio, S., Dazio, G., Cefalì, M., Wannesson, L., Frattini, M., & Froesch, P. (2022) · Cancers · doi:10.3390/cancers14174103 · Cited by 26 · see citing works
Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
Torres-Jiménez, J., Espinar, J. B., Bote, H., Berjaga, M. Z., Esteban-Villarrubia, J., Fraile, J. Z., & Paz-Ares, L. G. (2024) · Drugs · doi:10.1007/s40265-024-02030-7 · Cited by 22 · see citing works
Zhao, R., Yang, S., Xu, W., Jiang, F., Ran, P., Pan, L., Wang, J., Wang, W., Zhao, J., Wang, Y., et al. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03498-9 · Cited by 19 · see citing works
Zhang, M., Huang, Q., Yu, M., Xue, J., Huang, M., Lu, Y., & Zhang, Y. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-167 · Cited by 17 · see citing works
Jansen, J. P., Ragavan, M. V., Chen, C., Douglas, M. P., & Phillips, K. A. (2023) · Value in Health · doi:10.1016/j.jval.2023.08.010 · Cited by 18 · see citing works
Current perspectives of KRAS in non-small cell lung cancer
Harris, E., & Thawani, R. (2024) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2024.101106 · Cited by 16 · see citing works
Resistance to immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer
Li, Y., Hu, L., Peng, X., Xu, H., Tang, B., & Xu, C. S. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2021.102 · Cited by 13 · see citing works
Bontoux, C., Hofman, V., Brest, P., Ilié, M., Mograbi, B., & Hofman, P. M. (2022) · Cancers · doi:10.3390/cancers14071628 · Cited by 14 · see citing works
Spagnuolo, A., Maione, P., & Gridelli, C. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-948 · Cited by 14 · see citing works
How to manage KRAS G12C-mutated advanced non-small-cell lung cancer
Ricciuti, B., Mira, A., Andrini, E., Scaparone, P., Michelina, S. V., Pecci, F., Cantini, L., Giglio, A. D., Lamberti, G., Ambrogio, C., et al. (2022) · Drugs in Context · doi:10.7573/dic.2022-7-4 · Cited by 13 · see citing works
Landscape of targeted therapies for lung squamous cell carcinoma
Chen, Q., Zheng, X.-S., Cheng, W., & Li, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1467898 · Cited by 12 · see citing works
He, Q., Liu, X., Jiang, L., Liu, P., Xuan, W., Wang, Y., Meng, R., Feng, H., Lv, S., Miao, Q., et al. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2441499 · Cited by 13 · see citing works
Sciortino, C., Viglialoro, V., Nucci, M., Polito, M. G., Cortesi, E., Gelibter, A. J., Gazzaniga, P., Nicolazzo, C., Siringo, M., & Caponnetto, S. (2022) · Oncotarget · doi:10.18632/oncotarget.28230 · Cited by 12 · see citing works
Barlési, F., Tomasini, P., Karimi, M., Michiels, S., Raimbourg, J., Daniel, C., Janicot, H., Madroszyk, A., Audigier-Valette, C., Quoix, É., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0371 · Cited by 10 · see citing works
Single-cell and bulk sequencing analyses reveal the immune suppressive role of PTPN6 in glioblastoma
Zhang, X., Chen, J., Zhang, M., Liu, S., Wang, T., Wu, T., Li, B., Zhao, S., Wang, H., Li, L., et al. (2023) · Aging · doi:10.18632/aging.205052 · Cited by 9 · see citing works
Marković, F., Milin-Lazovic, J. S., Nikolić, N., Golubovic, A., Stjepanović, M., & Kontić, M. (2025) · Current Oncology · doi:10.3390/curroncol32060365 · Cited by 8 · see citing works
A comprehensive review of mechanisms underlying resistance to immune checkpoint inhibitors
Bertucci, A., -, D. T. K., Billon, E., Fernez, T., & Rochigneux, P. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1735741 · Cited by 9 · see citing works
Wang, M., Zhang, Y., Wu, S., Zhang, S.-Y., Shan, H.-L., Yang, X., Xu, X., Song, L.-Q., & Qu, S. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-449 · Cited by 8 · see citing works
Ding, M., Li, Y.-A., Lu, Z., & Hou, G. (2022) · BioMed Research International · doi:10.1155/2022/1734847 · Cited by 8 · see citing works
Lung Cancer Computational Biology and ResourcesPreprint
Cai, L., Xiao, G., Gerber, D. E., Minna, J. D., & Xie, Y. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a038273 · Cited by 8 · see citing works
Zhao, J., Wang, L., Zhou, A., Wen, S., Fang, W., Zhang, L., Duan, J., Bai, H., Zhong, J., Wan, R., et al. (2024) · Med · doi:10.1016/j.medj.2024.04.011 · Cited by 7 · see citing works
Caballé‐Perez, E., Hernández‐Pedro, N., Ramos-Ramírez, M., Barrios‐Bernal, P., Romero-Núñez, E., Lucio-Lozada, J., Ávila‐Ríos, S., Reyes‐Terán, G., Cardona, A. F., & Arrieta, O. G. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03279-2 · Cited by 7 · see citing works
Nakagawa, N., & Kawakami, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.952393 · Cited by 7 · see citing works
Abolfathi, H., Kordahi, M., Armero, V. E. S., Gagné, A., Desmeules, P., Orain, M., Fiset, P., Boudreau, D. K., Gaudreault, N., Lamaze, F. C., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108596 · Cited by 6 · see citing works
Erhart, C.-C., Cefalì, M., Mangan, D., Kasenda, B., & Wannesson, L. (2024) · Swiss Medical Weekly · doi:10.57187/s.3695 · Cited by 7 · see citing works
McMahon, D. J., McLaughlin, R. A., & Naidoo, J. (2024) · Cancers · doi:10.3390/cancers16030527 · Cited by 6 · see citing works
Sun, L., Zhou, Y., Handorf, E. A., Borghaei, H., Bauman, J. R., & Aggarwal, C. (2024) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2024.100755 · Cited by 5 · see citing works
Self-citationCantor, D. J., Nimeiri, H. S., Horn, L., West, M., Ben‐Shachar, R., Huerga, I., Patel, J. D., & Aggarwal, C. (2025) · Clinical Lung Cancer · doi:10.1016/j.cllc.2025.05.007 · Cited by 5 · see citing works
Self-citationGuo, X., Wang, J., Li, D., Wang, B., Zhu, H., & Guo, H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1467755 · Cited by 5 · see citing works
Targeting KRAS -Mutated NSCLC: Novel TKIs and Beyond
Cantor, D. J., & Aggarwal, C. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1658 · Cited by 5 · see citing works
Self-citationSpatial iTME analysis of KRAS mutant NSCLC and immunotherapy outcome
Zhao, D., Li, H., Mambetsariev, I., Mirzapoiazova, T., Chen, C., Fricke, J., Wheeler, D. L., Arvanitis, L. D., Pillai, R. K., Afkhami, M., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00626-6 · Cited by 5 · see citing works
First-line immunotherapy in non-small cell lung cancer: how to select and where to go
Mogavero, A., Cantale, O., Mollica, V., Anpalakhan, S., Addeo, A., Mountzios, G., Friedlaender, A., Kanesvaran, R., Novello, S., & Banna, G. L. (2023) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2024.2302356 · Cited by 5 · see citing works
Pathak, G. P., Shah, R., Castonguay, M., Cheng, A., Fris, J., Murphy, R. E., Darling, G. E., Ednie, A. C., French, D. G., Henteleff, H., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.70262 · Cited by 4 · see citing works
Ferrara, M. G., Stefani, A., Pilotto, S., Carbone, C., Vita, E., Salvatore, M. D., D’Argento, E., Sparagna, I., Monaca, F., Valente, G., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.792385 · Cited by 4 · see citing works
Mazzaschi, G., Perrone, F., Minari, R., Verzè, M., Azzoni, C., Bottarelli, L., Pluchino, M., Armillotta, M. P., Ubaldi, A., Altimari, A., et al. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.07.005 · Cited by 4 · see citing works
Colonese, F., Bulotta, A., Genova, C., Signorelli, D., Bonanno, L., Proto, C., Panel, I. I. N. D., & Cortinovis, D. L. (2024) · Biomedicines · doi:10.3390/biomedicines12122742 · Cited by 4 · see citing works
Kirsten rat sarcoma inhibitors in clinical development against nonsmall cell lung cancer
Li, Y., Hu, L., & Xu, C. S. (2021) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000808 · Cited by 3 · see citing works
Limited role of KRAS mutation in guiding immunotherapy in advanced non-small-cell lung cancer
Li, H., Liu, C., & Wang, Y. (2022) · Future Oncology · doi:10.2217/fon-2021-1488 · Cited by 3 · see citing works
Shen, H., & Li, C. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1385761 · Cited by 2 · see citing works
Eklund, E. Ä., Sayin, S. I., Jonsson, J. S., van Renswoude, H., Nyman, J., Hallqvist, A., Wiel, C., & Sayin, V. I. (2025) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2025.100880 · Cited by 2 · see citing works
Immune and Genomic Heterogeneity of MET-Altered Non–Small Cell Lung Cancer
Liu, M., Minne, R. L., Javeri, S., Johnson, D. B., Tomlins, S. A., Kimple, R. J., & Baschnagel, A. M. (2025) · JCO Precision Oncology · doi:10.1200/po-25-00048 · Cited by 2 · see citing works
Peters, S., Hochmair, M. J., Arbour, K. C., Rodríguez, L. P.-A., Reck, M., Leal, T. A. B., Lindsay, C. R., Shun, L., William, W. N., Spira, A. I., et al. (2026) · Future Oncology · doi:10.1080/14796694.2026.2651961 · Cited by 2 · see citing works
Hata, T., Sakaguchi, C., Hirano, K., Kobe, H., Ishida, M., Nakano, T., Tachibana, Y., Tamiya, N., Shiotsu, S., Takeda, T., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04125-8 · Cited by 2 · see citing works
Response to First-Line Pembrolizumab in Metastatic KRAS -Mutated Non-Small-Cell Lung Cancer
Rossi, S., Pagliaro, A., Finocchiaro, G., Marinello, A., Giordano, L., Bria, E., Stefani, A., Vitale, A., Toschi, L., D’Argento, E., et al. (2024) · Future Oncology · doi:10.2217/fon-2023-0952 · Cited by 2 · see citing works
Optimizing Therapeutic Approaches for Aggressive Molecular Subtypes of Metastatic NSCLC
Delasos, L. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.11.008 · Cited by 1 · see citing works
Jansen, J. P., Douglas, M. P., & Phillips, K. A. (2025) · Value in Health · doi:10.1016/j.jval.2025.07.025 · Cited by 1 · see citing works
Pham, T. H., Phạm, C. P., Nguyễn, T. T. H., & Nguyen, K. T. (2026) · Current Oncology · doi:10.3390/curroncol33040215 · Cited by 1 · see citing works
Gürçay, N., Demirağ, F., Yilmaz, M., Öz, İ., Cengiz, T. İ., Koçanoğlu, A., Karakaya, S., & Demir, Ö. F. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15135236 · Cited by 1 · see citing works
Basile, H. D. S., Elaidi, R., Maaradji, Z., Blons, H., BenDhiab, R., Gibault, L., & Fabre, E. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00283 · Cited by 1 · see citing works
Tajè, R., Ambrogi, V., Tacconi, F., Gallina, F. T., Alessandrini, G., Forcella, D., Buglioni, S., Visca, P., Patirelis, A., Cecere, F. L., et al. (2025) · Clinical Lung Cancer · doi:10.1016/j.cllc.2025.01.001 · Cited by 1 · see citing works
García-Pardo, M., & Garrido, P. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-838 · Cited by 1 · see citing works
Algorithme thérapeutique des CBNPC sans anomalie moléculaire actionnable
Pérol, M., Avrillon, V., Zalcman, G., & Scherpereel, A. (2021) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(21)00105-1
Traitement de 1re ligne des CBNPC métastatiques sans addiction oncogénique
Pérol, M. (2022) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(22)00014-3
Novel Biomarkers and Drug Targets in Non-Small Cell Lung Cancer
Dy, G. K. (2022) · European Medical Journal · doi:10.33590/emj/10113934
Algorithme thérapeutique des CBNPC sans mutation addictive
Cortot, A. B., Pérol, M., Avrillon, V., & Zalcman, G. (2022) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(22)00117-3
Clinical Trial Using Real World Data
Akamatsu, H. (2022) · Haigan · doi:10.2482/haigan.62.965
Algorithme thérapeutique des CBNPC sans mutation addictive
Mazières, J., Pérol, M., & Cortot, A. B. (2023) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(23)00141-6
Mechanisms of resistance to immunotherapy
Blauensteiner, B., Lentner, T., & Moreno‐Viedma, V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13376-3.00007-1 · Cited by 1 · see citing works
Algorithme thérapeutique des CBNPC sans mutation addictive
Moro‐Sibilot, D., Mazières, J., Berardi, G., Pérol, M., & Cortot, A. B. (2024) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(24)00089-2
Eklund, E. Ä., Sayin, S. I., Jonsson, J. S., van Renswoude, H., Nyman, J., Hallqvist, A., Wiel, C., & Sayin, V. I. (2025) · medRxiv · doi:10.1101/2025.04.09.25325505
Toffart, A., Mazières, J., Pérol, M., Berton, E., Cortot, A. B., & Moro‐Sibilot, D. (2025) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(25)00072-2
Huang, J. Z., Lei, J., Xiao, B., Kang, W., Sui, Z., Deng, Y., Jia, R., Huang, C., & Cai, S. (2025) · Respiratory Research · doi:10.1186/s12931-025-03429-w
Trécesson, S. D. C., East, P., Pillsbury, C. E., dos Santos, M. S., Cha, H., Colliver, E., Gilmore, T., Rana, S., Moore, C., Lighterness, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.25.690426
Sheffield, K. M., Puri, T., Thoele, K., Karu, H., Mansharamani, A., & Uprety, D. (2026) · Cancers · doi:10.3390/cancers18172869
- Authors
- Sun, L., Hsu, M., Cohen, R. B., Langer, C. J., Mamtani, R., & Aggarwal, C.
- Affiliations
- Abramson Cancer Center (US)
- Corresponding author
- Aggarwal, Charu
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2021-06-01
- Volume
- 7
- Issue
- 6
- Pages
- 937
- ISSN
- 2374-2437 (ISSN-L)
- PMC
- PMC8050787
- OpenAlex
- W3155198217
- Cited by
- 87
- References
- 7
- Citations by year
- 2026: 5 · 2025: 13 · 2024: 23 · 2023: 13 · 2022: 25 · 2021: 8
- FWCI
- 11.16
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (T32CA009679)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- KRAS mutation, non-small cell lung cancer, immune checkpoint inhibitors, first-line therapy, chemoimmunotherapy, immune checkpoint inhibitor monotherapy, treatment outcomes, predictive biomarkers
- MeSH terms
- Immune Checkpoint Inhibitors, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Proto-Oncogene Proteins p21(ras), B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
